Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients with Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant

Protocol No
ALLOVIR-AVM-003-HC
Phase
III
Summary

The purpose of this study is to determine if ALVR105 is safe and a good treatment for Hemorrhagic Cystitis

Description
Trial of Viralym-M (ALVR105) for Patients With Virus-Associated Hemorrhagic Cystitis after allo-HCT
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Leukemia, Hematologic/Blood Related Cancers, Other Blood Related, Lymphoma
ClinicalTrials.gov
go to website